We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher Introduces New Solutions for Fast and Sensitive Nucleic Acid Detection

By LabMedica International staff writers
Posted on 20 Jul 2023
Print article
Image: The Applied Biosystems QuantStudio 5 Dx Real-Time PCR System is on display at AACC 2023 (Photo courtesy of Thermo Fisher)
Image: The Applied Biosystems QuantStudio 5 Dx Real-Time PCR System is on display at AACC 2023 (Photo courtesy of Thermo Fisher)

Thermo Fisher Scientific Inc. (Waltham, MA; USA) is presenting its dynamic range of products at AACC 2023 that can help laboratories maximize productivity and innovation. In addition, Thermo Fisher is hosting industry-leading workshops where experts will be discussing the company’s latest innovations for preeclampsia testing with its new biomarkers PlGF and sFlt-1 that can help manage preeclampsia and neuroendocrine tumors.

During this session, Thermo Fisher is presenting two new product offers. The first is a new direct RT-qPCR system that can be used to amplify nucleic acid from inhibitor-enriched samples. The latest data demonstrates new reagents and workflow conditions that work best on saliva and serum samples. Second, the company will discuss the new Invitrogen Lyo-ready Bst DNA Polymerase for RT-LAMP isothermal amplification. This best-in-class enzyme demonstrates the highest speed, sensitivity, and resistance to inhibitor performance in LAMP reactions. Together, the Invitrogen Lyo-ready SuperScript IV Reverse Transcriptase and Invitrogen Lyo-ready RNaseOUT RNase Inhibitors offer the fastest solution for pathogen diagnostics using RT-LAMP.

At AACC 2023, Thermo Fisher is offering live demonstrations of its Indiko and Indiko Plus clinical and specialty chemistry analyzers that are easy-to-use, cost-effective, and designed for load-up and walk-away convenience. An intuitive user interface and many automated features help labs manage their daily workflow. These self-contained analyzers have small footprints and fit well in laboratories with space limitations. Thermo Fisher is also demonstrating the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System and Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System. Thermo Fisher is also offering live demonstrations of its new Diomni Enterprise software which combines instruments, assays, and consumables to streamline workflow from samples to clinical results.

Related Links:
Thermo Fisher Scientific Inc. 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.